Stem cell treatment for MS

Israel’s BrainStorm has received FDA approval to use its Nurown stem cells in a Phase 2 trial for the treatment of Multiple Sclerosis (MS). MS affects approximately 1 million individuals in the U.S. and 2.5 million individuals worldwide.  Nurown is already in a Phase 3 trial for ALS (see here).

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *